



LMA International NV

16 October 2007

Announcement to the Singapore Exchange

**LMA FILES PATENT INFRINGEMENT LITIGATION AGAINST AMBU
IN THE UNITED STATES**

The Laryngeal Mask Company Limited (Seychelles) (“LMC”) and LMA North America Inc. (“LMA North America”), both subsidiaries of mainboard-listed LMA International N.V. (“LMA”), have filed a patent infringement complaint against Ambu A/S (“Ambu”), Ambu's U.S. sales subsidiary, and Ambu's Chinese and Malaysian manufacturing subsidiaries.

Filed yesterday in the United States district court in San Diego, LMC and LMA North America claim that Ambu's AuraOnce, Aura40, AuraFlex, and AuraStraight brands of supraglottic airway management devices infringe United States Patents Nos. 5,303,697 and 7,156,100. The Ambu products compete against the LMA Unique, Classic, and Flexible airway devices.

LMC and LMA North America are seeking damages, treble damages for willful infringement, attorney's fees, pre-judgment and post-judgment interest, and an injunction, among other relief.

The patent infringement litigation should take approximately two years to reach a judgment. LMC and LMA North America have requested a trial by jury.

LMA is the global leader in the development and marketing of the LMA™ range of supraglottic airway management devices.

LMA International NV

PO Box 862, Osprey House, Old Street, Jersey, Channel Islands JE4 2ZZ

ENDS

NOTES:

LMA International NV

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ range of supraglottic airway management devices. These devices are used by physicians to allow

respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Germany, San Diego, California, and Melbourne, Australia. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.

LMA™ Airways

For over 20 years, The Laryngeal Mask Company Limited has been making advances in airway design and technology which have impacted directly on patient safety and comfort. British anaesthetist Dr Archie Brain designed the first LMA™ airway in 1988. Since then, LMA™ airways have been used over 200 million times around the world and are supported by over 2,500 published references. The LMA™ airway has become the most well-known and respected supraglottic airway device worldwide, with a full range of products designed for specialist clinical needs including routine anaesthesia, PPV, ENT surgery, the difficult airway and emergency situations.

LMA Patent Portfolio

LMA has an extensive patent portfolio that protects the key products in the LMA™ range, as well as new products currently under development. The Company's portfolio comprises an estimated 335 granted and pending patents worldwide, the majority of which have a significant unexpired term. Of the Company's granted patents, the earliest expiry date is 2008, and the latest is around 2025.